Valneva reported today its nine-month financial results ending September 30, 2020.
Q3 milestones included
- Major COVID-19 vaccine partnership with U.K. government
- Pre-clinical and industrialization activities on track
- Positive top-line results for Lyme Phase 2 studies
- First company to initiate Phase 3 study for chikungunya vaccine; EMA PRIME Designation granted
- New US military / DoD contract for IXIARO®
Cash position of €156 million at end of Q3, year-end outlook expected to exceed €180 million
Operating financial results impacted by second wave of COVID-19 pandemic
- Limited product sales in Q3
- Gross Margin impacted
- US military orders and supply rephased into Q4